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Effect of aluminum mobilization on hemoglobin during the first six
months after transplantation. We prospectively monitored 38 patients
for the first six months following successful renal cadaver allograft
transplantation. Hemoglobin increased from a mean of 8.2 0.3 g/dl to
13.4 0.3 g/dl (sEM), P < 0.001, plasma aluminum decreased from 1.3
0.2 molIliter to 0.46 0.04 imoII1iter, P < 0.001, and urinary
aluminum excretion which peaked at one week post-transplant, 5.5
1.3 molI24 hr decreased to 1.8 0.3 smol/24 hr, P < 0.001. Prior to
transplantation 22 patients had been prescribed aluminum-containing
phosphate binders. Following transplantation this group had persis-
tently greater plasma aluminum and urinary aluminum concentrations
which were sustained throughout the study period, compared with
those not given aluminum containing medicaments. Hemoglobin and
iron status were similar in the two groups prior to transplantation,
although red blood cell volume was smaller in those given aluminum-
containing phosphate binders, 89 0.9 fi (fentoliters) versus 95 1.6 fi,
P < 0.05. However, the percentage increase in hemoglobin following
transplantation was greater in the group not given aluminum prepara-
tions, 34 4% versus 7 5% at one month, 69 7% versus 37 7%
at three months, and 80 8% versus 56 8% at six months
respectively, all P < 0.05. This study suggests that aluminum mobili-
zation following successful renal transplantation may reduce the rate of
hemopoiesis.
Anemia is a recognized complication of chronic renal failure.
There are many factors which may contribute to this anemia,
including variable shortening of red blood cell survival, iron
deficiency, hyperspienism, repeated blood loss on hemodialy-
sis, bone marrow suppression by "uremic toxins" and alumi-
num toxicity [1—31. However, the crucial defect is probably the
inadequate production of erythropoietin, which is the major
hormonal regulator of red cell production and is produced
principally, but not solely, by the kidney [1—3].
Previous studies have shown that successful renal allograft
transplantation results in the correction of anemia between
three and six months following transplantation [4, 5]. Circulat-
ing erythropoietin concentrations have been reported to in-
crease and reach a plateau between the fourth and tenth days in
patients with immediate allograft function, and this is then
followed by an increase in the peripheral reticulocyte count [6].
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Aluminum can accumulate in patients with end-stage renal
failure as a result of hemodialysis using contaminated dialysate,
ingestion of aluminum-containing phosphate binders, and the
administration of parenteral fluids and blood products contam-
inated with aluminum [7]. Aluminum accumulation has been
reported to result in the development of a microcytic micro-
chromic anemia [8]. Aluminum can compete for key iron
binding sites during hemopoiesis [9] and interfere with some of
the rate limiting enzymes, such as delta-amino-levulinic acid
dehydrase [101. Studies have reported an increase in hematocrit
following aluminum chelation therapy with desferrioxamine in
regular hemodialysis patients with proven aluminum osteodys-
trophy [11]. Following successful renal allograft transplantation
aluminum can be mobilized from body stores [12]. We prospec-
tively investigated the effect of aluminum release following
renal transplantation on the rate of increase in hemoglobin in a
cohort of patients with primary renal function who were treated
with a standard immunosuppression protocol.
Methods
Patients
We prospectively measured urinary aluminum excretion in
100 consecutive, first cadaver renal allografts. In this study 24
patients were excluded as they had been transfused pre-, pen-
or post-operatively. Twenty-one patients were treated with
azathioprine, and as this drug has a bone marrow suppressive
effect they were excluded from study. Other exclusions were 11
patients with graft failure, four patients who died and six
patients with iron deficiency.
The remaining 38 successful, first-cadaver renal allograft
recipients with primary graft function were prospectively stud-
ied for the first six months following transplantation. The group
comprised 24 men and 14 women whose median age was 40
years (range 25 to 64). At the time of transplantation, 26 patients
(68%) were in receipt of regular thrice weekly hemodialysis
using reverse osmosis water purification, median duration 18
months (range 5 to 168); 12 patients (32%) had been treated with
continuous ambulatory peritoneal dialysis (CAPD) of a median
duration of 16 months (range 9 to 87).
The original cause of renal failure was glomerulonephritis in
19 cases (50%), chronic pyelonephritis in five (13%), two cases
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of diabetic nephropathy (5%), and one case each of hyperten-
sive nephrosclerosis, polycystic kidney disease, obstructive
uropathy and post-partum renal failure. In the remaining eight
cases (21%) no primary etiology could be confidently identified.
No patient had undergone bilateral host nephrectomy. Prior to
transplantation 23 patients (61%) were prescribed iron supple-
ments (ferrous sulphate), and an additional five (13%) were
commenced on iron supplements within one week of transplan-
tation. In all cases iron supplementation was maintained
throughout the study period. No patient in the study was given
a blood transfusion either immediately prior to transplantation
or during the study period.
Aluminum-containing phosphate binders had been prescribed
to 22 patients in the six months prior to transplantation, which
in all cases were discontinued at the time of transplantation.
The other 16 patients either did not require phosphate binders
or had been prescribed calcium carbonate. No one in this group
had been prescribed aluminum-based phosphate binders or
other medications known to contain aluminum for a minimum
of two years prior to transplantation. Prior to transplantation
three patients, all from the group prescribed aluminum-based
phosphate binders had undergone parathyroidectomy. Follow-
ing transplantation only one patient developed hypercalcemia
(serum calcium >2.7 mmollliter), and this settled spontaneously
without recourse to surgical intervention.
Patients were immunosuppressed with a single perioperative
dose of methyiprednisolone, 0.5 g, and cyclosporine, given
initially at 15 mgIkg day, in divided doses. Thereafter the dose
of cyclosporine was adjusted according to trough serum con-
centrations using a polyclonal antibody radioimmunoassay [131.
If patients had allograft rejection which did not resolve with
three consecutive daily doses of 0.5 g methyiprednisolone, then
oral prednisolone 20 mg daily was added to the cyclosporine
therapy. During the study 35 rejection episodes were diagnosed
in 20 patients (53%), 16 in the group prescribed aluminum-based
phosphate binders and 19 in the non-aluminum group. All
rejection episodes responded promptly to methyl prednisolone
therapy. At the end of the six month study period, 23 patients
remained on cyclosporine monotherapy (61%), and 15 patients
were prescribed additional oral prednisolone. No patient was
given azathioprine or received either polyclonal or monoclonal
antibody therapy.
During the study period 24 infective episodes were docu-
mented in the aluminum group and 10 in the non-aluminum
group. The majority were urinary tract infections (24; 71%),
followed by wound infection (4; 12%) and post-operative chest
infection (4; 12%).
Methods
Prior to transplantation iron status was assessed by measure-
ment of serum ferritin, iron and total iron binding capacity by
standard techniques. Patients were routinely discharged two
weeks after transplantation and attended the outpatient depart-
ment thrice weekly for the first month, weekly for the next two
months, and then every two weeks up to six months. Blood was
taken prior to transplantation for the measurement of hemoglo-
bin (Coulter STKR, Coulter, Luton, UK) and aluminum. At
each clinic visit and while an inpatient, a 24-hour urine collec-
tion was arranged and a corresponding blood sample taken.
Aluminum was measured in both urine and plasma by graphite
furnace atomic absorption spectroscopy [141. As aluminum is
ubiquitous, extreme care was taken in both obtaining and
preparing samples to prevent extraneous contamination. Sam-
ples were obtained without the use of gloves, placed in plastic
containers (acid prewashed) and transferred to the trace ele-
ment laboratory without delay. The samples were then poured,
not pipetted, into 5 ml aluminum-free plain plastic tubes, each
batch of tubes having been tested for possible aluminum con-
tamination. Samples were diluted using a clean acid-washed
pipette tip for each sample, into acid-washed autoanalyzer cups
on the autosampler carousel.
The analyses were performed on a 2380 Perkin Elmer atomic
absorption spectrophotometer linked to an HGA 500 graphite
furnace and AS4O autosampler. Background correction was
used for all analyses. The coefficient of variation of the analytic
technique over the time of the study was 11% at an aluminum
concentrations of 0.43 tmo1Jliter, 4.3% at 2.5 molIliter and
3.9% at 4.37 jsmot/liter. The graphite furnace program had been
well proven over several years. Plasma and urine creatinine
were measured using standard methods.
Statistical analysis
Statistical analysis was by Student's t-test, the Mann-Whit-
ney U test and analysis of variance (ANOVA) for intergroup
comparison, and the paired t-test and the Wilcoxon rank sum
pair test for intragroup analysis of parametric and non-paramet-
ric data, respectively. Correlation analysis was by Spearman's
rank sum test. In addition, the chi square test, with Yate's
correction, if appropriate, was also used. Statistical significance
was taken at or below the 5% level.
Results
The mean hemoglobin immediately prior to transplantation
was 8.2 0.28 gIdl (sEM), and initially declined to 7.4 0.21
gIdl after one week. Thereafter the hemoglobin steadily in-
creased following transplantation reaching 13.3 0.31 g/dl at
the end of the six month study (Fig. 1). No patient in the study
group developed post-transplant erythrocytosis that required
venesection.
The mean reticulocyte count at one month following trans-
plantation was 3.3 0.3% and was not different from that at
two months, 3.4 0.2%, but then declined to 2.9 0.4% at
three months and to 2.1 0.3% after six months, P < 0.05.
Similarly, the mean red cell volume decreased from 90.7 I fi
(fentoliters) at one month to 88.4 1 fi, P < 0.05 after two
months, then to 86.4 1 fi at three months, 86.0 1 fi at four
months, P < 0.001, to 85.8 1 fi at five months, and finally to
86.1 1 fi at six months.
Renal function, as determined by creatinine clearance,
steadily increased during the first six months following success-
ful renal transplantation (Fig. 1). There was no correlation
between renal function, as expressed as creatinine clearance
and the increase in hemoglobin following transplantation.
The mean plasma aluminum immediately prior to transplan-
tation was 1.3 0.18 mol/liter, and progressively declined
during the first six months following transplantation to 0.46
0.04 p,mol/liter (Fig. 1), but this was still greater than our normal
laboratory range of less than 0.4 molfliter [14]. There was no
correlation between the pretransplant plasma aluminum values
and the pretransplant hemoglobin (r = —0.1, P 0.9) but there
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was a negative correlation between pretransplant plasma alu-
minum concentration and red blood cell size (r = —0.54, P =
0.001). There was no correlation between the duration of
dialysis and the pretransplant plasma aluminum concentration.
The mean urinary aluminum excretion on the first post-
operative day was 2.6 0.8 molI24 hr and increased to 5.5
1.3 mol/24 hr after one week; thereafter there was a steady
decline in urinary excretion to 1.8 0.3 molI24 hr at six
months (Fig. 1). This compares with previous studies which
have reported an expected urinary aluminum excretion of 0.3 to
0.5 tmol/24 hr in normal healthy control subjects [141.
There were strong positive correlations between the plasma
aluminum concentration and urinary aluminum excretion fol-
lowing transplantation, with r = 0.76, P < 0.001 at one week, r
= 0.7, P < 0.001 at two weeks, r = 0.63, P < 0.001 at one
month, r = 0.63, P <0.001 at two months, r = 0.61, P <0.001
at three months, r = 0.61, P < 0.001 at four months, r = 0.54,
P < 0.001 at five months and r = 0.54, P < 0.001 at six months.
Subgroup analysis of those patients taking aluminum-contain-
ing phosphate binders prior to transplantation and those who
were not, did not show any difference in terms of iron status
prior to transplantation. The mean ferritin concentration in the
aluminum group was 128 36 ng/ml compared to 117 26
ng/ml in the aluminum free group. The serum iron concentra-
tions were 17.6 2.5 mol/liter and 16.8 1.9 mol/liter,
respectively, and were within our laboratory normal range of 8
to 35 tmolIliter. Similarly, there was no difference in the total
iron binding capacity between the groups, median 51 mol/liter
(interquartile range 41 to 56) in the aluminum group and 47
tmol/liter (38 to 50) in the other, During the study period 28
patients (74%) were maintained on iron supplements, and this
may account for the smaller reduction in serum ferritin to 88
25 ng/ml and 78 19 ng/ml observed during the study in the
aluminum group and aluminum free group, respectively. No
patient in the study had a serum ferritin and/or iron below the
normal reference range with an increased total iron binding
capacity to suggest true iron deficiency. Similarly, no patient
developed a microcytic blood film following transplantation.
The plasma aluminum prior to transplantation was greater in
the group prescribed aluminum-containing phosphate binders,
median 1.4 prnol/liter (0.75 to 2.4), compared with 0.6 jimol/
liter (0.4 to 0.8) in those not prescribed aluminum containing
medications, P < 0.05. Following transplantation the plasma
aluminum remained persistently greater in the aluminum group
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Fig. 1. increase in hemoglobin and changes in plasma and urinary aluminum concentration following successful renal transplantation in the study
group. Data are mean SEM. Symbols are: (A) * p < 0.05 vs. pre-Hb, ** P < 0.01 vs. pre-Hb; (B) * P < 0.01 vs. Ccr 1 week; (C) * P < 0.05 vs.
pre-Al, ** P < 0.01 vs. pre-Al; (D) * P < 0.05 vs. 1 week urinary Al; ** P <0.01 vs. 1 week urinary Al.
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Fig. 2. Changes in plasma and urinary aluminum following successful
renal transplantation in those patients prescribed aluminum-containing
phosphate binders (alucaps, U) and those either requiring no phos-
phate binders or prescribed calcium carbonate (no alucaps, --0--). *
<0.05 vs. alucaps. Data are median (interquartile range).
during the six months of the study (Fig. 2). Urinary aluminum
excretion was similarly greater in those patients prescribed
aluminum-containing phosphate binders prior to transplantation
(Fig. 2). Renal function, as assessed by creatinine clearance did
not differ between the groups following transplantation (Fig. 2).
There was no significant difference between the median
hemoglobin taken immediately prior to transplantation, 8.1 gIdl
(7.3 to 8.7) in the group prescribed aluminum-containing phos-
phate binders and 8.2 g/dl (7.1 to 8.5) in the other. Following
transplantation there was a greater increase in the hemoglobin
in the group which had not been given aluminum containing
medications, which was sustained over the six months of the
study (Fig. 3). Reticulocytosis was greater after the first month
following transplantation in the aluminum free group, 4.2
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Fig. 3. Change in hemoglobin following successful renal allograft
transplantation in those patients prescribed aluminum-containing
phosphate binders (alucaps, U) and those either requiring no phos-
phate binders or prescribed calcium carbonate (no alucaps, --0--).
Data are mean SEM. * P < 0.05 vs. alucaps.
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Fig. 4. Red blood cell mean corpuscular volume measured in fento-
liters (fi) prior to and during the first six months following successful
renal allograft transplantation in those patients prescribed aluminum
containing phosphate binders (alucaps, 0) and those either requiring
no phosphate binders of prescribed calcium carbonate (no alucaps,
--0--). * P < 0.05 vs. alucaps. Data are mean (interquartile range).
0.4% compared to 2.4 0.2% in the aluminum group, P < 0.01.
Thereafter, although greater in the aluminum free group, the
reticulocyte count was not statistically different (3.7 0.4% vs.
3.1 0.3% at three months, and 3.5 0.5% vs. 3.4 0.4% at
six months).
Red cell volume was smaller in the aluminum group com-
pared to the aluminum free group both prior to and following
transplantation (Fig. 4).
Discussion
We prospectively studied 38 patients with end-stage renal
failure who underwent successful cadaveric renal transplanta-
tion. Prior to transplantation no patient had biochemical indices
of iron deficiency and no patient was transfused in the pert-
operative period. Following transplantation the hemoglobin
initially declined at one week then progressively increased and
had not plateaued at the end of the six month study period. This
pattern of an initial reduction in hemoglobin would support
previous studies which have shown that in renal transplant
recipients with good primary function, erythropoietin peaks
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between the sixth and tenth postoperative day, and then this is
followed a few days later by an increased peripheral reticulo-
cyte count [5, 61.
During the study period renal function, as measured by
creatinine clearance, also increased, but there was no relation-
ship between hemoglobin and renal function. Although renal
erythropoietin production does depend upon renal function, the
ability of the kidney to sense oxygen delivery [151, and oxygen
availability [161, other workers have also not been able to
demonstrate any relationship between renal function and post-
transplant erythrocytosis [17]. Similarly there appears to be no
relationship between the erythropoietin concentration and he-
matocrit following transplantation, this may be due to various
factors including erythropoietin production by the recipient's
native kidneys, and the effect of renal tubular damage in the
transplanted kidney following acute tubular necrosis, acute
rejection episodes, cyclosporine toxicity and changes in plasma
volume [17]. Similarly, treatment with azathioprine may also
have had effects on post-transplant erythropoiesis [18].
As expected, patients treated for end-stage renal failure had
an increased plasma aluminum prior to transplantation. Follow-
ing transplantation plasma aluminum declined and after six
months was approaching normal plasma values. Urinary alumi-
num excretion peaked around one week following transplanta-
tion, supporting previous studies [14], and then steadily de-
clined. After six months urinary aluminum excretion remained
more than three-fold greater than normal. This would suggest
that although plasma aluminum values were approaching the
normal range these patients still had a significant aluminum
body burden, as shown by the persistently increased urinary
excretion. The strong positive correlations between plasma and
urinary aluminum following transplantation would suggest that
the plasma aluminum represents the flux between the mobiliza-
tion of aluminum from body tissues and urinary aluminum
excretion.
Patients prescribed aluminum-containing phosphate binders
had an estimated daily oral aluminum intake of 500 to 2000
mg/day [13], compared with an estimated 5 to 7 mg/day in those
taking no phosphate binders or calcium based medicaments.
There were no statistically significant differences between the
two groups in terms of the patient age, mode of dialysis, iron
status, and/or in the prescription of iron supplements, immuno-
suppressive regimen. However, those patients prescribed alu-
minum containing phosphate binders had been dialyzed for a
longer, but not statistically greater period, median 26 months (5
to 168) compared with 12 months (5 to 33) for the others. There
was, however, no correlation between the duration of dialysis
treatment and plasma aluminum concentration prior to and
following transplantation. Similarly, there was no relationship
between the duration of dialysis treatment and the increase in
hemoglobin following transplantation. This would suggest that
other factors associated with duration of dialysis did not have a
significant effect on post-transplant erythrocytosis [1, 2, 7].
Following transplantation plasma and urinary aluminum con-
centrations were greater in the group which had been given
aluminum containing rnedicaments prior to transplantation.
Although hemoglobin was similar in both groups prior to
transplantation, those in the aluminum group had smaller red
blood cell volumes, as may be expected from earlier published
work on the effects of aluminum toxicity [7]. Following trans-
plantation the percentage of increase in hemoglobin and reticu-
locytosis was less in those patients with the greater aluminum
body burden, as shown by the increased urinary aluminum
excretion. Aluminum is probably initially mobilized from soft
tissue stores, including liver, spleen and muscle [19] and then
from bone [19]. Once in the plasma aluminum, although the
majority of it is bound to transferrin, can compete for iron
receptor sites. Thus, although the majority of any mobilized
aluminum will be excreted in the urine, some will be able to
enter the bone marrow and compete with iron for receptor sites.
Previous studies have shown that the key mitochondrial rate
limiting enzyme in the synthesis of hem-delta-aminolevulinic
acid dehydrase, can be inactivated when incubated with alumi-
num in vitro [20], and that enzyme activity is reduced in patients
with increased plasma aluminum concentrations [10]. Other
workers have reported that dialysis patients with increased
aluminum body burden showed a reduced response to treat-
ment with erythropoietin, and this was associated with an
increased protoporphyrin concentration, suggesting an addi-
tional effect of aluminum competing for the final enzyme in the
hem synthesis pathway: ferrochetolase [21].
The results of this study suggest that aluminum mobilization
following renal transplantation may reduce post-operative
erythrocytosis and support the work of earlier studies which
showed that aluminum chelation with desferrioxamine in pa-
tients treated for end-stage renal failure who were aluminum
overloaded resulted in an increase in hemoglobin [11]. Other
workers reported an increase in hemoglobin following desferri-
oxamine treatment in dialysis patients who were thought to
have modest levels of aluminum, and this was associated with
an increase in red blood cell size [22]. In these studies aluminum
chelation with desferrioxamine may have resulted in an in-
crease in the amount of bioavailable iron and thus increased
erythropoiesis. This contention is supported by the observa-
tions that when aluminum is bound to transferrin [23] it inhibits
iron uptake at the cellular level partly by down-regulating
transferrin-receptor expression and partly by interfering with
the intracellular release of iron from transferrin [241. By inter-
fering with the bioavailability of iron [24], aluminum accumu-
lation may therefore result in a microcytic anemia, as found in
iron deficiency states, and in addition may also reduce the rate
of erythropoiesis by interfering with some of the key rate-
limiting enzymes of hem synthesis [20, 211.
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